Clinical trials: Recurrent Head and Neck Carcinoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
This phase II trial with a safety run-in component will evaluate whether the addition of pembrolizumab to Stereotactic Body Radiation Therapy (SBRT) re-irradiation will improve the progression-free survival for patients with…
- Trial name
- KEYSTROKE (NCT03546582)
- Testing
- Pembrolizumab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 18 sites in United States, Canada
- Volunteers
- 86 people
- Sponsor
- RTOG Foundation, Inc.
Thoracic Solid Malignant Tumor
Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
To evaluate the safety and efficacy of Boron Neutron Capture Therapy (BNCT) in patients with recurrent thoracic solid tumors that are difficult to treat with standard radiation therapy or drug therapy and are unresectable.
- Trial name
- NCT06603987
- Testing
- BNCT, ［18F］FBPA
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Stella Pharma Corporation
Metastatic Head-and-neck Squamous-cell Carcinoma
Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma
In France, the incidence of head and neck squamous cell carcinomas (HNSCC) is 16 000 new cases/year. During these last years, many new chemotherapies and targeted therapies have been developed improving significantly the overall…
- Trial name
- CIRCUTEC (NCT02119559)
- Testing
- Blood analysis by EPISPOT and CellSearch®
- Where
- France
- Volunteers
- 115 people
- Sponsor
- University Hospital, Montpellier
Oral Squamous Cell Carcinoma
Survival Benefit of Elective Neck Dissection in T1,2N0M0 Oral Squamous Cell Carcinoma
Controversy over surgical treatment of clinically negative neck in early stage oral squamous cell carcinoma revolves around the uncertainty of its impact on patient prognosis.
- Trial name
- NCT01334320
- Testing
- elective neck dissection
- Where
- 4 sites in China
- Volunteers
- 448 people
- Sponsor
- Sun Yat-sen University
Head and Neck Neoplasms, Carcinoma, Squamous Cell
A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck
This is a Phase 2, multi-center, open label study of ARQ 501 in patients with locally advanced, recurrent or metastatic squamous cell cancer of the head and neck (SCCHN).
- Trial name
- NCT00358930
- Testing
- ARQ 501
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Head and Neck Cancer
MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer
RATIONALE: Diagnostic procedures, such as specialized types of magnetic resonance imaging (MRI), may help in planning radiation therapy that does less damage to normal tissues.
- Trial name
- NCT00984074
- Testing
- blood-oxygen-level-dependent functional magnetic resonance imaging, diffusion tensor imaging, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Trial name
- NCT00068497
- Testing
- gefitinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
This phase II trial is studying how well sorafenib works in treating patients with advanced anaplastic thyroid cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by…
- Trial name
- NCT00126568
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma (ESCC)
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
This study is a single-arm clinical trial to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab combined with chemotherapy in the first-line treatment of patients with recurrent or metastatic esophageal squamous…
- Trial name
- NCT07290010
- Testing
- Iparomlimab and Tuvonralimab combined with chemotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Hebei Medical University Fourth Hospital
Head and Neck Cancer
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
This is a study of Nivolumab in combination with experimental medication BMS-986205 compared to the standard of care EXTREME regimen in head and neck cancer that has come back after initial treatment, or is widespread when first…
- Trial name
- NCT03386838
- Testing
- Nivolumab, BMS-986205, Cetuximab
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Head and Neck Cancer
Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for skin cancer and cancer that is metastatic to the skin.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer
- Trial name
- NCT00023790
- Testing
- silicon phthalocyanine 4
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT05063552
- Testing
- Atezolizumab, Bevacizumab, Biospecimen Collection
- Where
- 172 sites in United States
- Volunteers
- 430 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)
This study was designed to compare the efficacy and safety of YL201 with Investigator's choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least…
- Trial name
- NCT06629597
- Testing
- YL201, Docetaxel, Capecitabine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Metastatic Cancer, Recurrent Cancer
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
This study is to determine the safety of IRX-2 Regimen combined with Nivolumab in patients with recurrent metastatic solid tumors.
- Conditions
- Metastatic Cancer, Recurrent Cancer, Solid Tumor, Renal Cell Carcinoma
- Trial name
- NCT03758781
- Testing
- IRX 2, Nivolumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Thyroid Cancer
Study of External Beam Radiotherapy to Thyroid Carcinoma
The primary objective of this study is to estimate the 5 year locoregional control rate after External Beam Radiotherapy (EBRT) in the patient with locally advanced differentiated thyroid cancer.
- Trial name
- NCT01173289
- Testing
- External Beam Radiotherapy
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- National Cancer Center, Korea
Ovarian Cancer, Fallopian Tube Cancer
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
Activity of COTI-2 has been demonstrated in various cancer tumor models. With its p53- and AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment of patients with gynecologic malignancies or head…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- COTI2-101 (NCT02433626)
- Testing
- COTI2, Cisplatin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Critical Outcome Technologies Inc.
Neoplasms
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
This study is open to adults with advanced cancer (solid tumors) and people with advanced head and neck cancer. The study has 2 parts.
- Trial name
- NCT04958239
- Testing
- BI 765179, Ezabenlimab, Pembrolizumab
- Where
- 48 sites in United States, Australia and 13 more
- Volunteers
- 151 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Cancer
Title XELOX FOR SALIVARY GLAND CANCERS
The goal of this clinical research study is to find out how effective oxaliplatin and capecitabine are against advanced cancer of the salivary gland.
- Trial name
- NCT00101075
- Testing
- Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Colorectal Cancer
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Vaccines made from a person's white blood cells that have been treated in the laboratory may make the body build an immune response to kill tumor cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00027534
- Testing
- TRICOM-CEA(6D)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Michael Morse, MD
Esophageal Squamous Cell Carcinoma
A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma.
This is a Phase 1, open-label, multicenter study to assess the safety, tolerability, and preliminary efficacy of IPM514 in patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
- Trial name
- NCT07203898
- Testing
- IPM514
- Volunteers
- 36 people
- Sponsor
- Beijing Immupeutics Medicine Technology Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.